Abstract
The Cancer Immunotherapy Pilot Program (also known as Patents 4 Patients) provides fast-track review to patent applications describing methods of treating cancer with immunotherapy, such as chimeric antigen receptor ("CAR")- T cell treatments. This article explores considerations for claiming CAR-T cell treatments, including court rulings and examiner guidelines on patentable subject matter in the life sciences, the Federal Circuit's decision in NantKwest, Inc. v. Lee in 2017, and pending applications and current litigation over CAR-T cell treatments.
Files
Metadata
- Subject
Health Law and Policy
Science and Technology Law
- Journal title
Boston College Intellectual Property and Technology Forum
- Volume
2018
- Pagination
1-33
- Date submitted
29 November 2022
- Related URL